On October 22, 2025, Avadel Pharmaceuticals PLC entered into a Transaction Agreement for Alkermes plc to acquire it for $18.50 per share in cash, along with a potential additional $1.50 per share based on performance milestones. This acquisition will result in Avadel becoming a wholly owned subsidiary of Alkermes.